Real-World Safety Analysis Reveals Key Adverse Event Patterns for Lutetium-177-PSMA-617 in Advanced Prostate Cancer
核心洞察
A comprehensive analysis of 7,654 adverse event reports from the FDA's FAERS database identified 33 statistically significant safety signals for Lutetium-177-PSMA (搜索)-617 (Pluvicto®) in advanced prostate cancer treatment.
Most adverse events occurred within the first three months of treatment, with nervous system disorders showing particularly rapid onset within the first 10 days post-administration.
Patients weighing 90 kg or more represented nearly one-quarter of cases and showed amplified adverse event incidence, suggesting need for weight-based dosing considerations.
A comprehensive real-world safety analysis of Lutetium-177-PSMA (搜索)-617 (Pluvicto®) has revealed critical insights into adverse event patterns for this groundbreaking radiopharmaceutical therapy in advanced prostate cancer. The study, analyzing 7,654 patient reports from the FDA's Adverse Event Reporting System (FAERS) between April 2022 and December 2024, identified 33 statistically significant safety signals that provide crucial guidance for clinical practice.
Temporal Distribution of Adverse Events
The analysis revealed a distinct temporal pattern in adverse event onset, with most complications manifesting within the first three months following treatment initiation. Of 295 valid patient records with complete timing data, 190 cases (64.41%) experienced adverse events within the first three months, with a median onset time of 54 days. The shortest onset occurred on the same day as medication administration, while the longest was recorded at 552 days.
Particularly noteworthy was the rapid emergence of nervous system disorders, which demonstrated a significant reduction in late versus early onset (OR = 0.41; 95% CI: 0.22–0.82), indicating these neurologic adverse events predominantly occur within the first 10 days after administration. This temporal clustering may reflect acute radiation-related effects on nerve endings or radioligand infusion reactions.
Weight-Based Risk Considerations
Demographic analysis revealed that patients weighing 90 kg or more comprised nearly one-quarter (24.3%) of the 350 cases with available weight data, with a median weight of 77.80 kg. This substantial proportion of heavier patients showed amplified adverse event incidence and significance, suggesting that individualized dosing strategies or enhanced supportive measures may be required to optimize safety profiles for this population.
Comprehensive Safety Signal Detection
Using four independent pharmacovigilance algorithms—Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)—researchers identified 33 statistically significant signals from an initial pool of 649 distinct adverse event terms. These signals spanned across 10 System Organ Class categories.
At the System Organ Class level, "General disorders and administration site conditions" demonstrated the strongest signal with ROR = 14.01 (95% CI 13.42–14.62) and high reporting frequency (n = 7,691, 73.05%). The "Investigations" category, representing laboratory abnormalities, accounted for 7.78% of reports (n = 819).
Hematologic and Laboratory Abnormalities
The study confirmed well-established hematologic toxicities while providing quantitative real-world validation. Fifteen significant adverse event signals correlated with the drug's pharmacologic action, including laboratory test abnormalities, anemia, platelet count decreased, hemoglobin decreased, and full blood count decreased. These findings align with clinical trial data from the pivotal VISION study, which reported Grade ≥3 hematologic adverse reactions including anemia (12.9% vs. 3.8% in controls), thrombocytopenia (7.9% vs. 0.5%), and lymphocytopenia (7.8% vs. 0%).
The mechanism of bone marrow suppression appears multifactorial, potentially involving radiation exposure of normal bone marrow tissue in patients with extensive prostate cancer infiltration. Prior chemotherapy or hormone therapy may have reduced patients' bone marrow reserves, exacerbating hematologic damage after Lutetium-177-PSMA (搜索)-617 administration.
Novel Safety Considerations
Beyond expected hematologic effects, the analysis uncovered consistent high-signal adverse events including xerostomia (dry mouth), which was the only troublesome symptom to meet criteria across all four analytical algorithms (n = 29 cases). This finding reflects the targeted nature of the therapy, as physiological sites expressing prostate-specific membrane antigen (PSMA (搜索)), such as salivary and lacrimal glands, may be affected by the highly targeted β-particle radiation.
Other significant signals included subdural hematoma, spinal cord compression, hepatic lesion, creatinine renal clearance decreased, and spinal cord infection, highlighting the need for comprehensive monitoring across multiple organ systems.
Clinical Outcomes and Mortality
Analysis of treatment outcomes revealed concerning mortality data, with 975 records (12.70%) of adverse events leading to death among the 1,599 reports with clearly documented outcomes. Additionally, 227 records (3.0%) resulted in hospitalization or prolonged hospital stay, and 16 records (0.2%) involved life-threatening conditions.
Implications for Clinical Practice
The study's findings emphasize the need for heightened clinical vigilance, particularly during the first three months of treatment. The identification of early-onset neurologic symptoms within the first 10 days suggests implementing daily symptom checklists and prompt supportive measures including hydration, antiemetics, or corticosteroids during this high-risk window.
For laboratory monitoring, the prominent "Investigations" signal supports intensified surveillance including complete blood counts and renal and hepatic panels at baseline, weekly for the first month, and monthly thereafter to detect emerging hematologic or biochemical abnormalities.
Study Limitations and Future Directions
The researchers acknowledged several limitations inherent to the FAERS database, including lack of comprehensive patient exposure details, reporting biases, and potential confounding by indication. The database cannot establish causality between the drug and adverse events, nor can it accurately calculate incidence rates. Advanced prostate cancer patients frequently experience systemic symptoms due to tumor burden, prior therapies, or comorbidities, which can precipitate similar adverse events.
Despite these limitations, the study provides valuable real-world evidence that complements clinical trial data. The rigorous application of multiple disproportionality analysis techniques and cross-validation through four statistical algorithms delivers high confidence in the detected associations, paving the way for improved safety guidelines and patient monitoring protocols.
As Lutetium-177-PSMA (搜索)-617 continues to expand globally for advanced prostate cancer treatment, this comprehensive safety analysis offers critical insights for optimizing patient care while managing the complex adverse event profile of this innovative radiopharmaceutical therapy.